SEC Tracker
Get the app
TNGX · XBRL financial data

Tango Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (TNGX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue115*620124*53540*00
Research and development2731*38393334*36333132*3437
General and administrative99*11111111*1111910*1523
Total operating expenses3640*49494445*48444042*4960
Operating income (loss)(26)(35)*(42)(30)(33)(41)*(43)(41)14(42)*(49)(60)
Other income (expense)22*2221*1111*11
Income tax expense (benefit)00*0000*00(0)(0)*00
Net income (loss)(22)(31)*(38)(26)(29)(38)*(40)(39)16(39)*(46)(55)
Earnings per share, basic USD per share(0.23)(0.29)*(0.35)(0.24)(0.27)(0.34)*(0.36)(0.35)0.14(0.29)*(0.32)(0.37)
Earnings per share, diluted USD per share(0.23)(0.29)*(0.35)(0.24)(0.27)(0.34)*(0.36)(0.35)0.13(0.31)*(0.32)(0.37)
Weighted average shares, basic millions of shares97105*108108109112*110111111133*144150
Weighted average shares, diluted millions of shares97105*108108109112*110111118126*144150

Balance sheet

CSV

Fiscal quarters (TNGX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents596661525370583958112158346
Marketable securities30127128227124018815814294231222668
Prepaid and other current assets10986888911101218
Total current assets3713473523283012662251901643543921,032
Property and equipment, net101010998887766
Right-of-use asset444442414039403837363534
Total assets4284034063813523162742382103994361,074
Accounts payable334142332122
Total current liabilities434643443838364018221420
Lease liability, non-current373736353534343232313029
Total liabilities15214914213412311710810350534449
Accumulated deficit(340)(371)(409)(435)(464)(502)(541)(580)(564)(603)(649)(704)
Total stockholders' equity2772532642482292001671351603463921,025
Total liabilities and equity4284034063813523162742382103994361,074
Common shares outstanding (cover page) millions of shares102107107107107108108111135143145169

Cash flows

CSV

Fiscal quarters (TNGX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(22)(31)*(38)(26)(29)(38)*(40)(39)16(39)*(46)(55)
Stock-based compensation5*5*78*7*7*77*7*6*1117*
Net cash from operating activities(31)*(27)*(38)(24)*(33)*(37)*(42)(37)*(31)*(30)*(44)(39)*
Purchases of property and equipment0*0*00*0*0*01*0*0*(0)(0)*
Net cash from investing activities(57)*34*(11)13*33*52*3117*47*(136)*10(446)*
Proceeds from issuing common stock——420*0*———————
Net cash from financing activities80*1*431*2*1*01*3*219*80673*
Net change in cash(8)*8*(6)(10)*2*16*(11)(19)*19*54*45188*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Tango Therapeutics3460(39)*168.6M26.1 quarters 10-QJun 30, 2026
Elite Pharmaceuticals3932101.1B— 10-QJun 30, 2026
Iovance Biotherapeutics58121not reported462.7M— 10-QSep 30, 2026
Opko Health38465(36)*742.5M10.8 quarters 10-QSep 30, 2026
Savara42not reported(30)*205.5M5.8 quarters 10-QJun 30, 2026
Xencor601172.6*75.0M— 10-QSep 30, 2026
KalVista Pharmaceuticals21441(14)53.2M19.7 quarters 10-QMar 31, 2026
Evolus4278(1.9)*66.2M7.7 quarters 10-QSep 30, 2026
Kura Oncology7021(63)*89.0M8.3 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.